Literature DB >> 23446216

Linkage between Anaplasma marginale outer membrane proteins enhances immunogenicity but is not required for protection from challenge.

Susan M Noh1, Joshua E Turse, Wendy C Brown, Junzo Norimine, Guy H Palmer.   

Abstract

The prevention of bacterial infections via immunization presents particular challenges. While outer membrane extracts are often protective, they are difficult and expensive to isolate and standardize and thus are often impractical for development and implementation in vaccination programs. In contrast, individual proteins, which are easily adapted for use in subunit vaccines, tend to be poorly protective. Consequently, identification of the specific characteristics of outer membrane-based immunogens, in terms of the antigen contents and contexts that are required for protective immunity, represents a major gap in the knowledge needed for bacterial vaccine development. Using as a model Anaplasma marginale, a persistent tick-borne bacterial pathogen of cattle, we tested two sets of immunogens to determine whether membrane context affected immunogenicity and the capacity to induce protection. The first immunogen was composed of a complex of outer membrane proteins linked by covalent bonds and known to be protective. The second immunogen was derived directly from the first one, but the proteins were individualized rather than linked. The antibody response induced by the linked immunogen was much greater than that induced by the unlinked immunogen. However, both immunogens induced protective immunity and an anamnestic response. These findings suggest that individual proteins or combinations of proteins can be successfully tested for the ability to induce protective immunity with less regard for overall membrane context. Once protective antigens are identified, immunogenicity could be enhanced by cross-linking to allow a reduced immunogen dose or fewer booster vaccinations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23446216      PMCID: PMC3647754          DOI: 10.1128/CVI.00600-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  30 in total

1.  Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors.

Authors:  Theodora Fifis; Anita Gamvrellis; Blessing Crimeen-Irwin; Geoffrey A Pietersz; Jie Li; Patricia L Mottram; Ian F C McKenzie; Magdalena Plebanski
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

2.  Immunization of cattle with the MSP-1 surface protein complex induces protection against a structurally variant Anaplasma marginale isolate.

Authors:  G H Palmer; A F Barbet; G H Cantor; T C McGuire
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

3.  Association and evidence for linked recognition of type IV secretion system proteins VirB9-1, VirB9-2, and VirB10 in Anaplasma marginale.

Authors:  Kaitlyn Morse; Junzo Norimine; Guy H Palmer; Eric L Sutten; Timothy V Baszler; Wendy C Brown
Journal:  Infect Immun       Date:  2011-10-28       Impact factor: 3.441

4.  Induction of protective immunity by using Anaplasma marginale initial body membranes.

Authors:  N Tebele; T C McGuire; G H Palmer
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

5.  Humoral and cell-mediated immunity in mice to a 17-kilodalton lipoprotein of Francisella tularensis expressed by Salmonella typhimurium.

Authors:  A Sjöstedt; G Sandström; A Tärnvik
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

6.  Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine.

Authors:  K R Turbyfill; A B Hartman; E V Oaks
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

7.  Immunization of cattle with a 36-kilodalton surface protein induces protection against homologous and heterologous Anaplasma marginale challenge.

Authors:  G H Palmer; S M Oberle; A F Barbet; W L Goff; W C Davis; T C McGuire
Journal:  Infect Immun       Date:  1988-06       Impact factor: 3.441

8.  Immune serum against Anaplasma marginale initial bodies neutralizes infectivity for cattle.

Authors:  G H Palmer; T C McGuire
Journal:  J Immunol       Date:  1984-08       Impact factor: 5.422

9.  Immunization with an isolate-common surface protein protects cattle against anaplasmosis.

Authors:  G H Palmer; A F Barbet; W C Davis; T C McGuire
Journal:  Science       Date:  1986-03-14       Impact factor: 47.728

10.  Characterization of lymphocyte subpopulations and major histocompatibility complex haplotypes of mastitis-resistant and susceptible cows.

Authors:  Yong Ho Park; Yi Seok Joo; Joo Youn Park; Jin San Moon; So Hyun Kim; Nam Hoon Kwon; Jong Sam Ahn; William C Davis; Christopher J Davies
Journal:  J Vet Sci       Date:  2004-03       Impact factor: 1.672

View more
  8 in total

1.  Structural Basis for Recombinatorial Permissiveness in the Generation of Anaplasma marginale Msp2 Antigenic Variants.

Authors:  Telmo Graça; Marta G Silva; Alla S Kostyukova; Guy H Palmer
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

2.  Identification of a T-Cell Epitope That Is Globally Conserved among Outer Membrane Proteins (OMPs) OMP7, OMP8, and OMP9 of Anaplasma marginale Strains and with OMP7 from the A. marginale subsp. centrale Vaccine Strain.

Authors:  James R Deringer; Elkin G Forero-Becerra; Massaro W Ueti; Joshua E Turse; James E Futse; Susan M Noh; Guy H Palmer; Wendy C Brown
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

3.  Reduced Infectivity in cattle for an outer membrane protein mutant of Anaplasma marginale.

Authors:  Francy L Crosby; Kelly A Brayton; Forgivemore Magunda; Ulrike G Munderloh; Karen L Kelley; Anthony F Barbet
Journal:  Appl Environ Microbiol       Date:  2015-01-16       Impact factor: 4.792

4.  Targeted mutagenesis in Anaplasma marginale to define virulence and vaccine development against bovine anaplasmosis.

Authors:  Paidashe Hove; Swetha Madesh; Arathy Nair; Deborah Jaworski; Huitao Liu; Jonathan Ferm; Michael D Kleinhenz; Margaret A Highland; Andrew K Curtis; Johann F Coetzee; Susan M Noh; Ying Wang; Dominica Genda; Roman R Ganta
Journal:  PLoS Pathog       Date:  2022-05-16       Impact factor: 7.464

5.  Subdominant Outer Membrane Antigens in Anaplasma marginale: Conservation, Antigenicity, and Protective Capacity Using Recombinant Protein.

Authors:  Deirdre R Ducken; Wendy C Brown; Debra C Alperin; Kelly A Brayton; Kathryn E Reif; Joshua E Turse; Guy H Palmer; Susan M Noh
Journal:  PLoS One       Date:  2015-06-16       Impact factor: 3.240

6.  Knockout of an outer membrane protein operon of Anaplasma marginale by transposon mutagenesis.

Authors:  Francy L Crosby; Heather L Wamsley; Melanie G Pate; Anna M Lundgren; Susan M Noh; Ulrike G Munderloh; Anthony F Barbet
Journal:  BMC Genomics       Date:  2014-04-11       Impact factor: 3.969

Review 7.  Anaplasma marginale: Diversity, Virulence, and Vaccine Landscape through a Genomics Approach.

Authors:  Rosa Estela Quiroz-Castañeda; Itzel Amaro-Estrada; Sergio Darío Rodríguez-Camarillo
Journal:  Biomed Res Int       Date:  2016-08-17       Impact factor: 3.411

8.  A vaccine using Anaplasma marginale subdominant type IV secretion system recombinant proteins was not protective against a virulent challenge.

Authors:  Macarena Sarli; María B Novoa; Matilde N Mazzucco; Marcelo L Signorini; Ignacio E Echaide; Susana T de Echaide; María E Primo
Journal:  PLoS One       Date:  2020-02-21       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.